Johnson & Johnson (JNJ) Total Debt (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Debt of $55.0 billion for Q1 2026, up 14.72% sequentially from $47.9 billion in Q4 2025, and up 5.23% YoY from $52.3 billion in Q1 2025.
Johnson & Johnson (JNJ) Total Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Total Debt data on file, last reported at $55.0 billion in Q1 2026.
- Quarterly Total Debt rose 5.23% year-over-year to $55.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 billion (up 5.23% YoY) and the FY2025 annual result came in at $47.9 billion, up 30.84% from the prior year.
- Total Debt climbed to $55.0 billion in Q1 2026 per JNJ's latest filing, from $47.9 billion in the prior quarter.
- The five-year high for Total Debt was $55.0 billion in Q1 2026, with the low at $29.3 billion in Q4 2023.
- Average Total Debt over 5 years is $40.5 billion, with a median of $38.1 billion recorded in 2023.
- Year-over-year, Total Debt soared 59.61% in 2023 and plunged 36.43% in 2024.
- Johnson & Johnson's Total Debt stood at $32.0 billion in 2022, then fell by 8.41% to $29.3 billion in 2023, then climbed by 24.89% to $36.6 billion in 2024, then soared by 30.84% to $47.9 billion in 2025, then advanced by 14.72% to $55.0 billion in 2026.
- Business Quant data shows JNJ's Total Debt at $55.0 billion in Q1 2026, $47.9 billion in Q4 2025, and $45.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 43.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 54.99 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -19.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 54.99 Bn |
| Dec 28, 2025 | 47.93 Bn |
| Sep 28, 2025 | 45.80 Bn |
| Jun 29, 2025 | 50.76 Bn |
| Mar 30, 2025 | 52.25 Bn |
| Dec 29, 2024 | 36.63 Bn |
| Sep 29, 2024 | 35.75 Bn |
| Jun 30, 2024 | 41.49 Bn |
| Mar 31, 2024 | 33.63 Bn |
| Dec 31, 2023 | 29.33 Bn |
| Oct 1, 2023 | 29.92 Bn |
| Jul 2, 2023 | 45.60 Bn |
| Apr 2, 2023 | 52.91 Bn |
| Jan 1, 2023 | 39.64 Bn |
| Oct 2, 2022 | 32.03 Bn |
| Jul 3, 2022 | 32.60 Bn |
| Apr 3, 2022 | 33.15 Bn |
| Jan 2, 2022 | 33.75 Bn |
| Oct 3, 2021 | 33.93 Bn |
| Jul 4, 2021 | 33.48 Bn |